Cargando…
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice...
Autores principales: | Massó-Vallés, Daniel, Soucek, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226798/ https://www.ncbi.nlm.nih.gov/pubmed/32260326 http://dx.doi.org/10.3390/cells9040883 |
Ejemplares similares
-
The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
por: Savino, Mauro, et al.
Publicado: (2011) -
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
por: Demma, Mark J., et al.
Publicado: (2019) -
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
por: Beaulieu, Marie-Eve, et al.
Publicado: (2023) -
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2015) -
Ibrutinib repurposing: from B-cell malignancies to solid tumors
por: Massó-Vallés, Daniel, et al.
Publicado: (2016)